Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance by Almeda-Valdes, Paloma et al.
CARDIO
VASCULAR 
DIABETOLOGY
Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
http://www.cardiab.com/content/9/1/26
Open Access ORIGINAL INVESTIGATION
© 2010 Almeda-Valdes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Original investigation Total and high molecular weight adiponectin have 
similar utility for the identification of insulin 
resistance
Paloma Almeda-Valdes, Daniel Cuevas-Ramos, Roopa Mehta, Francisco J Gomez-Perez, Ivette Cruz-Bautista, 
Olimpia Arellano-Campos, Mariana Navarrete-Lopez and Carlos A Aguilar-Salinas*
Abstract
Background: Insulin resistance (IR) and related metabolic disturbances are characterized by low levels of adiponectin. 
High molecular weight adiponectin (HMWA) is considered the active form of adiponectin and a better marker of IR 
than total adiponectin. The objective of this study is to compare the utility of total adiponectin, HMWA and the HMWA/
total adiponectin index (SA index) for the identification of IR and related metabolic conditions.
Methods: A cross-sectional analysis was performed in a group of ambulatory subjects, aged 20 to 70 years, in Mexico 
City. Areas under the receiver operator characteristic (ROC) curve for total, HMWA and the SA index were plotted for the 
identification of metabolic disturbances. Sensitivity and specificity, positive and negative predictive values, and 
accuracy for the identification of IR were calculated.
Results: The study included 101 men and 168 women. The areas under the ROC curve for total and HMWA for the 
identification of IR (0.664 vs. 0.669, P = 0.74), obesity (0.592 vs. 0.610, P = 0.32), hypertriglyceridemia (0.661 vs. 0.671, P = 
0.50) and hypoalphalipoproteinemia (0.624 vs. 0.633, P = 0.58) were similar. A total adiponectin level of 8.03 μg/ml was 
associated with a sensitivity of 57.6%, a specificity of 65.9%, a positive predictive value of 50.0%, a negative predictive 
value of 72.4%, and an accuracy of 62.7% for the diagnosis of IR. The corresponding figures for a HMWA value of 4.25 
μg/dl were 59.6%, 67.1%, 51.8%, 73.7% and 64.2%.
The area under the ROC curve of the SA index for the identification of IR was 0.622 [95% CI 0.554-0.691], obesity 0.613
[95% CI 0.536-0.689], hypertriglyceridemia 0.616 [95% CI 0.549-0.683], and hypoalphalipoproteinemia 0.606 [95% CI
0.535-0.677].
Conclusions: Total adiponectin, HMWA and the SA index had similar utility for the identification of IR and metabolic 
disturbances.
Background
Adiponectin is a peptide hormone produced by adipose
tissue, involved in glucose and lipid metabolism [1-4].
The high molecular weight form is considered the active
fraction of adiponectin; for this reason it is considered a
better marker of metabolic disturbances than total adi-
ponectin [5-7].
The average plasma concentration of this hormone
ranges between 5 and 10 μg/ml; levels vary according to
sex, body fat distribution, and metabolic status [8]. Men
have approximately 15% lower levels compared to women
[9]. Adiponectin concentration is lower in obesity, specif-
ically central obesity [10] and studies confirm that levels
increase with weight loss [11]. Low adiponectin concen-
trations have also been registered in individuals with cor-
onary artery disease [12]. Finally, persons with diabetes
have lower concentrations of this hormone compared to
non- diabetics; levels are also low in states of hyperinsu-
linemia and glucose intolerance. Moreover, when adjust-
ing for weight and body fat percentage, insulin sensitivity
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is independently associated with the adiponectin concen-
tration [13].
The quantification of insulin resistance is desirable in
clinical practice since this metabolic state is a treatable
precursor of diabetes mellitus [14]. Established direct
methods to quantify insulin sensitivity, such as the hyper-
insulinemic euglycemic clamp, are complex and time
consuming. Surrogate indexes are available, but there are
no universal cutoff points to define IR. Adiponectin may
be a useful marker for insulin resistance and a variable
that can integrate the abnormalities of the metabolic syn-
drome. As yet, few studies have determined the utility of
adiponectin for this purpose. In addition, it is not know
whether the high molecular weight form is superior in
the evaluation of IR. The aim of this study is to evaluate
the utility of total adiponectin, HMWA and the SA index
for the identification of IR and metabolic disturbances in
a Mexican population.
Methods
Participants
A m b u l a t o r y  s u b j e c t s  a g e d  2 0  t o  7 0  y r  w e r e  r e c r u i t e d
between March and July 2008 in Mexico City. The popu-
lation consisted of medium-income healthy workers
without a personal history of metabolic abnormalities. To
avoid confounding factors known to affect plasma adi-
ponectin concentration the following exclusion criteria
were applied: fever (temperature ≥ 38°C), hospitalization
in the previous two weeks, known diabetes, arterial
hypertension, dyslipidemia, coronary heart disease or a
condition with equivalent risk (carotid disease, peripheral
artery disease, and aortic aneurysm), congestive heart
failure, stroke, chronic renal disease, active hepatic dis-
ease, chronic diseases or any other acute or chronic
inflammatory illness. These criteria were evaluated by a
questionnaire and in the case of diabetes, renal insuffi-
ciency and hypertension by the measurement of fasting
glucose, serum creatinine and blood pressure. Subjects
were also excluded if they were on any medication known
to affect the metabolic profile (anti-hypertensives, statins,
fibrates, metformin, thiazolidinediones, and salicylic
acid). The Ethics Committee approved the protocol and
all participants gave written informed consent.
Study protocol
A questionnaire was administered to all participants;
demographic data and medical history including smoking
habit were obtained. Height, weight, waist circumference,
and blood pressure were measured. Blood pressure was
measured twice, after a 5 minute rest between measure-
ments, and the average value was used for data analysis.
Blood samples were collected after a 9 to 12-hour fasting
period, centrifugated, and refrigerated at -70°C. All assays
were carried out on serum samples (except for adiponec-
tin that was measured in plasma) in the laboratory of the
Department of Endocrinology and Metabolism. This lab-
oratory is certified by the External Comparative Evalua-
tion of Laboratories Program of the College of American
Pathologists. Glucose was measured using the glucose
oxidase method (Boehringer Mannheim, Germany), total
cholesterol, and triglycerides were measured using an
enzymatic method (Boehringer Mannheim, Germany),
HDL-cholesterol was measured after precipitation using
phosphotungstic acid and Mg2+, low density lipoprotein
(LDL)-cholesterol concentration was estimated by the
Friedewald formula, plasma insulin was determined by a
MEIA assay (Abbott Laboratories), total adiponectin and
HMWA concentrations were measured using commercial
assays (Millipore, Mexico).
Briefly, the HMWA assay is a sandwich ELISA. Firstly
the adiponectin molecule is captured by a monoclonal
anti-adiponectin antibody coating the wells; secondly a
polyclonal anti-adiponectin antibody binds to the cap-
tured molecules. Finally, a streptavidin-horseradish per-
oxidase conjugate binds to this complex. The enzyme
activity is measured spectrophotometrically at 450 nm.
Prior treatment of the plasma samples removes hexa-
meric and trimeric adiponectin allowing for the specific
measurement of HMWA.
Definitions
Obesity was defined as a BMI of at least 30 kg/m2, hyper-
triglyceridemia was considered present with a triglycer-
ide level ≥ 150 mg/dl, hypoalphalipoproteinemia was
defined as HDL-cholesterol < 40 mg/dl in men and < 50
mg/dl in women. IR was evaluated and considered pres-
ent when either: 1) the homeostasis model assessment of
insulin resistance (HOMA-IR) was ≥ 2.5; 2) insulin sensi-
tivity (HOMA2%S) estimated by the HOMA2 calculator
v2.2 (Diabetes Trials Unit, University of Oxford) was <
75%, and 3) the triglyceride/HDL-cholesterol index was ≥
3. The MS was defined according to the National Educa-
tion Cholesterol Education Program's Adult Treatment
Panel III (ATP-III) and the International Diabetes Federa-
tion (IDF) criteria [15,16].
Statistics
Normally distributed data, identified using Kolmogorov-
Smirnov test, were expressed as mean ± standard devia-
tion (SD). Variables with a skewed distribution were
reported as median [interquartile range] [IQR]. Differ-
ences between groups were analyzed with the U-Mann
Whitney or Kruskal-Wallis tests. Spearman's correlation
coefficients were used to explore the association between
total adiponectin, HMWA and SA index and IR estima-
tions. ROC curves were plotted and comparisons of the
area under the curve were performed as described by De
Long et al. [17] using Stata version 10 (College Station,Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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TX). Other statistical analyses were performed using
SPSS Software version 15 (SPSS, Inc., Chicago IL.).
Results
The study included 269 individuals (101 men and 168
women). The mean age was 40.1 ± 9.46 years and the
mean BMI was 27.7 ± 4.26 kg/m2. The study population
characteristics are shown in Table 1. Using the ATP-III
definition, 28.6% of the study population fulfilled criteria
for the MS. When using the IDF criteria the prevalence of
the MS rose to 37.9%.
Plasma total adiponectin and HMWA levels in the study 
population
There was a close correlation between the concentration
of total adiponectin and HMWA (r = 0.890, P < 0.001).
There was also a moderate concordance between individ-
uals with total and HMWA below and above percentile 50
(kappa = 0.732, P < 0.001).
Consistent with the results of previous studies [7,9],
total adiponectin and HMWA levels were higher in
women than in men (total adiponectin 9.49 [5.31] vs. 6.85
[2.78] μg/ml, P < 0.001, HMWA 5.7 [4.25] vs. 3.5 [2.65]
μg/ml,  P  < 0.001). Thirty two participants (22.8% of
women) were post-menopausal. Adiponectin and
HMWA concentrations did not differ between pre and
post-menopausal women (total adiponectin 9.5 [4.72] vs.
9.9 [6.48] μg/ml, P  = 0.122, HMWA 5.7 [3.90] vs. 6.5
[6.10] μg/ml, P = 0.067). Total adiponectin and HMWA
concentrations were lower in obese vs. non-obese indi-
viduals (total adiponectin 7.56 [3.63] vs. 8.7 [4.40] μg/ml,
P = 0.028, HMWA 4.10 [2.82] vs. 5.00 [3.90] μg/ml, P =
0.008).
In addition, when comparing subjects with or without
the MS the concentrations of total and HMWA were sig-
nificantly lower in subjects who fulfilled MS criteria.
When classifying the participants by gender, this differ-
ence was not significant for men (Table 2).
Concentration of total and HMWA levels associated with 
insulin resistance
We evaluated total and HMWA concentrations by insulin
tertiles. Both forms of adiponectin decreased signifi-
cantly across the three insulin tertiles (total adiponectin
9.77 [4.58] vs. 8.27 [4.42] vs. 7.15 [3.79] μg/ml, P < 0.001),
HMWA 5.7 [4.45] vs. 4.6 [3.6] vs. 3.7 [2.85] μg/ml, P <
0.001) (Figure 1).
A significant correlation was found between total adi-
ponectin and the surrogate markers for insulin resistance.
An almost identical correlation was encountered between
HMWA and these markers; however, the correlation was
lower for the SA index (Table 3).
Total and HMWA concentration were significantly
lower in individuals with IR estimated using HOMA-IR,
triglyceride/HDL-cholesterol index and HOMA2%S.
When dividing the population by gender this difference
remained significant for all the surrogates of IR except
HOMA2%S in males (Table 4).
Utility of total adiponectin and HMWA for the identification 
of IR and metabolic disturbances
We plotted ROC curves to compare the utility of plasma
total adiponectin level, HMWA and SA index for the iden-
tification of IR and metabolic disturbances. The AUC for
total adiponectin was not significantly different to that of
HMWA for the identification of IR estimated by HOMA-
IR (total adiponectin 0.664 [95% CI 0.597-0.732] vs.
HMWA 0.669 [95% CI 0.603-0.735], P = 0.743), triglycer-
ide/HDL-cholesterol index (total adiponectin 0.717 [95%
CI 0.655-0.778] vs. HMWA 0.730 [95% CI 0.670-0.790], P
Table 1: Characteristics of the study population
Total
(n = 269)
Men
(n = 101)
Women
(n = 168)
P
Age (yr) 40.1 ± 9.49 40.5 ± 10.15 39.9 ± 9.42 0.582
Systolic pressure (mmHg) 111.1 ± 15.13 115.2 ± 15.00 108.5 ± 14.30 0.001
Diastolic pressure (mmHg) 74.5 ± 11.55 77.7 ± 9.98 72.6 ± 11.84 < 0.001
BMI (kg/m2) 27.7 ± 4.26 27.7 ± 3.81 27.7 ± 4.72 0.465
Glucose (mmol/liter) 4.92 ± 1.00 4.93 ± 0.58 4.91 ± 1.30 0.088
Triglycerides (mmol/liter) 1.46 [0.77] 1.61 [0.94] 1.37 [0.81] < 0.001
Cholesterol (mmol/liter) 5.20 [1.42] 5.12 [1.61] 5.21 [1.44] 0.987
HDL-c (mmol/liter) 1.16 [0.36] 1.01 [0.28] 1.21 [0.44] < 0.001
LDL-c (mmol/liter) 3.34 [1.08] 3.36 [1.20] 3.32 [1.05] 0.850
Insulin (pmol/liter) 65.28 [40.97] 68.75 [45.83] 63.19 [39.44] 0.180
Values are means ± SD, or median [IQR]. Number of subjects in each group is indicated in parentheses.Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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= 0.417), and HOMA2%S (total adiponectin 0.617 [95%
CI 0.549-0.684] vs. HMWA 0.623 [95% CI 0.556-0.690], P
= 0.698) (Figure 2).
In addition, the area under the ROC curves for total
adiponectin and HMWA were not significantly different
for the identification of metabolic abnormalities; obesity
(total adiponectin 0.592 [95% CI 0.510-0.673] vs. HMWA
0.610 [95% CI 0.531-0.690], P  = 0.32); hypertriglyceri-
demia (total adiponectin 0.661 [95% CI 0.596-0.726] vs.
HMWA 0.671 [95% CI 0.607-0.736], P  = 0.504); and
hypoalphalipoproteinemia (total adiponectin 0.624 [95%
CI 0.555-0.692] vs. HMWA 0.633 [95% CI 0.564-0.702], P
= 0.582).
The utility of the SA index for the identification of IR
and related metabolic disturbances showed an inferior
performance compared with total adiponectin and
HMWA concentrations; for IR estimated by HOMA
0.622 [95% CI 0.554-0.691], triglyceride/HDL-choles-
terol index 0.663 [95% CI 0.598-0.729], and HOMA2%S
0.603 [95% CI 0.535-0.671]. The areas under the ROC
curves were also lower for the identification of metabolic
abnormalities; obesity 0.613 [95% CI 0.536-0.689], hyper-
triglyceridemia 0.616 [95% CI 0.549-0.683], and hypoal-
phalipoproteinemia 0.606 [95% CI 0.535-0.677]. When
we analyzed the population stratifying by gender, the
resultant conclusions with respect to the areas under the
ROC curves of adiponectin, HMWA and the SA index
were similar as those derived from the total population
(Table 5).
A total adiponectin level of 8.03 μg/ml was associated
with a sensitivity of 57.6%, a specificity of 65.9%, a posi-
tive predictive value of 50.0%, a negative predictive value
of 72.4%, and an accuracy of 62.7% for the diagnosis of IR
using the HOMA-IR index. The corresponding figures
Table 2: Concentrations of total and HMWA in patients with and without the metabolic syndrome
Total adiponectin
(μg/ml)
P HMWA
(μg/ml)
P
ATP criteria
All (n = 269)
Metabolic syndrome (n = 77) 7.26 [3.57] 0.006 4.10 [3.07] 0.007
No metabolic syndrome (n = 192) 8.91 [4.84] 5.05 [4.03]
Men (n = 101)
Metabolic syndrome (n = 30) 6.44 [2.94] 0.183 3.25 [2.13] 0.245
No metabolic syndrome (n = 71) 7.32 [2.65] 3.50 [3.00]
Women (n = 168)
Metabolic syndrome (n = 47) 8.68 [4.58] 0.024 4.60 [5.00] 0.037
No metabolic syndrome (n = 121) 10.06 [4.91] 5.80 [4.20]
IDF criteria
All (n = 269)
Metabolic syndrome (n = 102) 7.27 [3.39] < 0.001 3.95 [2.48] < 0.001
No metabolic syndrome (n = 167) 9.11 [4.98] 5.40 [4.40]
Men (n = 101)
Metabolic syndrome (n = 45) 6.68 [2.79] 0.123 3.20 [1.80] 0.114
No metabolic syndrome (n = 56) 7.52 [2.93] 3.55 [3.48]
Women (n = 168)
Metabolic syndrome (n = 57) 8.68 [4.33] 0.002 4.60 [4.55] 0.007
No metabolic syndrome (n = 111) 10.48 [4.71] 6.20 [4.40]
Values are medians [IQR]. Number of subjects in each group is indicated in parentheses.Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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for a HMWA level of 4.25 μg/dl were 59.6%, 67.1%, 51.8%,
73.7% and 64.2%, respectively. When using the triglycer-
ide/HDL-cholesterol index, the sensitivity of a total adi-
ponectin level of 7.76 μg/ml was 54.5%, specificity 80.5%,
positive predictive value 79.4%, negative predictive value
56.2%, and accuracy 65.4%. The corresponding figures for
a HMWA level of 4.65 μg/ml were 64.7%, 73.5%, 77.1%,
60.1%, and 68.4%, respectively. Finally, when considering
the HOMA2%S value, a total adiponectin value of 8.25
μg/ml yielded a sensitivity of 52.4%, specificity 59.9%,
positive predictive value 53.3%, negative predictive value
59%, and accuracy of 56.3%. The corresponding figures
for a HMWA level of 4.25 μg/ml were 52%, 66.3%, 75.4%,
41.0%, and 56.7%.
Discussion
In recent years, several markers have been proposed for
the screening, diagnosis, and therapeutic monitoring of
insulin resistant patients [18]. However, all have problems
that limit their use to research studies [19]. Not one suc-
ceeds in integrating the global assessment of the meta-
bolic abnormalities that may increase the risk for
developing type 2 diabetes and cardiovascular outcomes.
Adiponectin is a promising biomarker of insulin resis-
tance. Low adiponectin levels are associated with the
majority of the metabolic syndrome traits and are related
to an increased risk for having type 2 diabetes [20,21].
This hormone is not prone to degradation and is only
minimally affected by diurnal variations, pre- vs. post-
prandial status, and acute infections. Adiponectin levels
can be assessed by either of three variables: total adi-
ponectin, HMWA and the SA index. Here, we compare
the diagnostic properties of these variables for detecting
insulin resistance (assessed using surrogate markers) and
other metabolic abnormalities in a population composed
of apparently healthy adults. Total adiponectin, HMWA
and the SA index had similar utility for the identification
of the metabolic abnormalities. Our results suggest that
Figure 1 Box plots of the concentrations of total and HMWA divided by insulin tertiles. A. Change in total adiponectin levels by insulin tertiles 
(9.77 [4.58] vs. 8.27 [4.42] vs. 7.15 [3.79] μg/ml, P < 0.001). B. Change in HMWA levels by insulin tertiles (5.7 [4.45] vs. 4.6 [3.6] vs. 3.7 [2.85] μg/ml, P < 0.001).
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Table 3: Correlation between total adiponectin, HMWA and SA index and estimators of IR
Adiponectin High Molecular Weight Adiponectin HMWA/adiponectin
ρ P ρ P ρ P
Fasting insulin -0.330 0.001 -0.323 0.001 -0.230 0.001
HOMA-IR -0.332 0.001 -0.325 0.040 -0.228 0.001
HOMA2S -0.329 0.001 -0.323 0.001 -0.231 0.001
Triglyceride/HDL cholesterol -0.458 0.001 -0.459 0.001 -0.302 0.001
HOMA-IR: homeostasis model assessment of insulin resistance
HOMA2S: insulin sensitivity estimated by the HOMA2 calculator v2.2 (Diabetes Trials Unit, University of Oxford)Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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Table 4: Concentrations of total and HMWA in patients with and without insulin resistance
Total adiponectin
(μg/ml)
P HMWA
(μg/ml)
P
HOMA-IR
All (n = 269)
Insulin resistance (n = 100) 7.05 [3.70] < 0.001 3.70 [2.90] < 0.001
No insulin resistance (n = 169) 8.96 [4.78] 5.30 [4.50]
Men (n = 101)
Insulin resistance (n = 42) 6.20 [3.15] 0.049 3.15 [2.43] 0.046
No insulin resistance (n = 59) 7.34 [2.65] 3.80 [2.80]
Women (n = 168)
Insulin resistance (n = 58) 8.73 [3.66] < 0.001 4.70 [3.35] < 0.001
No insulin resistance (n = 110) 10.76 [5.36] 6.45 [4.58]
Triglyceride/HDL-cholesterol
All (n = 269) 7.33 [3.51] < 0.001 3.90 [3.08] < 0.001
Insulin resistance (n = 156) 9.90 [4.84] 5.90 [4.20]
No insulin resistance (n = 113)
Men (n = 101) 6.70 [3.03] 0.024 3.20 [2.15] 0.004
Insulin resistance (n = 78) 8.17 [2.98] 5.10 [4.40]
No insulin resistance (n = 23)
Women (n = 168) 8.70 [4.44] < 0.001 4.75 [4.45] < 0.001
Insulin resistance (n = 78) 10.85 [4.73] 6.40 [4.43]
No insulin resistance (n = 90)
HOMA2%S
All (n = 269)
Insulin resistance (n = 123) 7.97 [3.74] < 0.001 4.20 [3.23] < 0.001
No insulin resistance (n = 146) 8.70 [4.74] 4.95 [4.58]
Men (n = 101)
Insulin resistance (n = 47) 6.61 [3.28] 0.115 3.20 [2.80] 0.240
No insulin resistance (n = 54) 7.33 [2.71] 3.55 [2.63]
Women (n = 168)
Insulin resistance (n = 76) 9.01 [4.62] 0.001 4.90 [3.70] <0.001
No insulin resistance (n = 92) 10.76 [5.15] 6.55 [4.63]
Values are medians [IQR]. Number of subjects in each group is indicated in parentheses.Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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plasma total adiponectin may provide clinical informa-
tion of the same diagnostic value as HMWA. This finding
may stimulate the use of adiponectin in clinical and epi-
demiological settings because the measurement of total
adiponectin is better standardized, cheaper and more
accessible than the other two approaches.
The highly significant correlation with insulin resis-
tance makes adiponectin a powerful marker for diabetic
risk. Several groups have shown that a low adiponectin
level predicts the incidence of diabetes in children [22]
and adults from several ethnic backgrounds [23]. Its high
molecular weight form is the active fraction of adiponec-
tin, is selectively down-regulated in IR states [5,14], and
has been proposed as the best approach to evaluate adi-
ponectin concentrations. However, the studies that sup-
port this conclusion have a small sample size [24], are
Figure 2 Area under the ROC curve of total and HMWA for the diagnosis of IR. A. Area under the ROC curve of total (0.664 [95% CI 0.597-0.732]) 
and HMWA (0.669 [95% CI 0.603-0.735]) for the identification of IR considering HOMA-IR. B. Area under ROC curve of total (0.717 [95% CI 0.655-0.778]) 
and HMWA (0.730 [95% CI 0.670-0.790]) for the identification of IR considering triglyceride/HDL-cholesterol index. C. Area under ROC curve of total 
(0.617 [95% CI 0.549-0.684] and HMWA (0.623 [95% CI 0.556-0.690]) for the identification of IR considering HOMA2%S.
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post hoc analysis of studies designed for other purposes
[25] or include biased populations (i.e. individuals with
cardiovascular disease) [5]. For example, Basu et al. eval-
uated adiponectin complex distribution in 11 type 2 dia-
betic and 7 nondiabetic subjects. Total adiponectin was
lower in the diabetic subjects primarily due to a reduction
of HMWA [24]. However, the limited sample size of this
study does not allow for the evaluation of adiponectin or
HMWA as a diagnostic test for IR. Hara et al. reported
that HMWA was better than total adiponectin for the
detection of IR [5]. In this study, the population consisted
of patients with diabetes or those who had had a coronary
angiography. The authors estimated IR (by calculating the
HOMA index) and they reported a greater area under the
ROC curve for HMWA of 0.713 (95% CI 0.620-0.805)
than that found for total adiponectin of 0.615 (95% CI
0.522-0.708, P = 0.016). In our study we investigated the
utility of total vs. HMWA for the identification of IR and
related metabolic disturbances in an adult Mexican
cohort. This population had no factors known to inter-
fere with adiponectin concentrations. Our results showed
a similar area under the ROC curve for both total adi-
ponectin 0.664 [95% CI 0.597-0.732] and HMWA 0.669
[95% CI 0.603-0.735], P = 0.743). The same conclusion
was reached for all surrogate markers of insulin resis-
tance. We believe that our results differ from previous
reports because of the characteristics of the population
under study. Our study sample is representative of per-
sons in whom a clinical indicator of IR is needed for early
identification of diabetes risk.
In addition, no difference between the three
approaches was found in the areas under the ROC curves
Table 5: AUC of total and HMWA for the identification of IR and related metabolic abnormalities
All
(n = 269)
Women
(n = 168)
Men
(n = 101)
IR by HOMA-IR
Total adiponectin 0.664 [0.597-0.732] 0.705 [0.622-0.788] 0.615 [0.501-0.729]
HMWA 0.669 [0.603-0.735] 0.693 [0.608-0.777] 0.617 [0.506-0.728]
SA index 0.622 [0.554-0.691] 0.631 [0.541-0.721] 0.584 [0.472-0.697]
IR by triglyceride/HDL-cholesterol index
Total adiponectin 0.717 [0.655-0.778] 0.670 [0.587-0.753] 0.655 [0.530-0.779]
HMWA 0.730 [0.670-0.790] 0.661 [0.579-0.744] 0.696 [0.557-0.835]
SA index 0.663 [0.598-0.729] 0.604 [0.518-0.690] 0.592 [0.475-0.777]
IR by HOMA2%S
Total adiponectin 0.617 [0.549-0.684] 0.654 [0.569-0.738] 0.591 [0.479-0.704]
HMWA 0.623 [0.556-0.690] 0.664 [0.582-0.747] 0.568 [0.456-0.680]
SA index 0.603 [0.535-0.671] 0.657 [0.574-0.740] 0.524 [0.411-0.638]
Obesity
Total adiponectin 0.592 [0.510-0.673] 0.591 [0.485-0.697] 0.633 [0.507-0.758]
HMWA 0.610 [0.531-0.690] 0.608 [0.504-0.713] 0.637 [0.519-0.756]
SA index 0.613 [0.536-0.689] 0.607 [0.510-0.705] 0.637 [0.518-0.756]
Hypertriglyceridemia
Total adiponectin 0.661 [0.596-0.726] 0.650 [0.561-0.738] 0.550 [0.434-0.666]
HMWA 0.671 [0.607-0.736] 0.634 [0.545-0.724] 0.604 [0.488-0.720]
SA index 0.616 [0.549-0.683] 0.572 [0.480-0.664] 0.586 [0.471-0.701]
Hypoalphalipoproteinemia
Total adiponectin 0.624 [0.555-0.692] 0.621 [0.535-0.707] 0.672 [0.565-0. 780]
HMWA 0.633 [0.564-0.702] 0.631 [0.545-0.716] 0.657 [0.538-0.776]
SA index 0.606 [0.535-0.677] 0.604 [0.516-0.691] 0.597 [0.473-0.721]
Values are areas [95% confidence interval]. Number of subjects in each group is indicated in parentheses.Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
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for the identification of other metabolic disturbances
(obesity, hypertriglyceridemia, hypoalphalipoproteine-
mia and IR). These findings suggest that adiponectin is of
value for the identification of IR and metabolic distur-
bances. If this turns out to be the case, adiponectin may
be a marker for global metabolic status. For this reason
we attempted to estimate an adiponectin threshold for
the identification of IR. The cutoff points used had a rea-
sonable sensitivity and specificity. Further studies are
needed to assess the diagnostic performance of these cut-
off points in other populations.
One of the disadvantages of adiponectin is that the
assay for its measurement is not widely available and is
expensive. In addition, the HMWA is even more expen-
sive and difficult to implement compared to the total adi-
ponectin method. However, adiponectin measurements
may be useful in the future to identify patients at risk for
metabolic alterations and to monitor treatment results.
The cross sectional design, the use of surrogate markers
(instead of the euglucemic hyperinsulinemic clamp) to
measure insulin action and a moderate sample size are
the main limitations of our study.
Conclusions
In this study, total adiponectin was as useful as HMWA
and the SA index in evaluating metabolic status. In addi-
tion, there was a similar association between total and
HMWA in assessing IR and related metabolic abnormali-
ties.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PA-V, DC-R and CA-S participated in the design, interpretation of the study,
analysis of the data, and review of the manuscript. RM and FG-P participated in
the review of the manuscript. IC-B, OA-C and MN-L participated in the method-
ology of the study. All authors have read and approved the final manuscript.
Acknowledgements
We express our gratitude to the laboratory personnel of the Department of 
Endocrinology and Metabolism of the Instituto Nacional de Ciencias Médicas y 
Nutrición "Salvador Zubirán".
Author Details
Departamento de Endocrinología y Metabolismo Instituto Nacional de 
Ciencias Médicas y Nutrición "Salvador Zubirán" 14000 México D.F., México
References
1. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and 
characterization of GBP28, a novel gelatin-binding protein purified 
from human plasma.  J Biochem 1996, 120:803-812.
2. Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin. More than just 
another fat cell hormone?  Diabetes Care 1996, 26:2442-2450.
3. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, 
Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, 
Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, 
Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived 
hormone adiponectin reverses insulin resistance associated with both 
lipoatrophy and obesity.  Nat Med 2001, 7:941-946.
4. Menzaghi C, Trischitta V, Doria A: Genetic influences of adiponectin on 
insulin resistance, type 2 diabetes, and cardiovascular disease.  
Diabetes 2007, 56:1198-1209.
5. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, 
Nagai R, Kadowaki T: Measurement of the high-molecular weight form 
of adiponectin in plasma is useful for the prediction of insulin 
resistance and metabolic syndrome.  Diabetes Care 2006, 29:1357-1362.
6. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro 
T, Tomita M, Tobe T: A novel enzyme-linked immunosorbent assay 
specific for high-molecular-weight adiponectin.  J Lipid Res 2006, 
47:1572-1582.
7. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, 
Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y: Comparison of 
serum high-molecular weight (HMW) adiponectin with total 
adiponectin concentrations in type 2 diabetic patients with coronary 
artery disease using a novel enzyme-linked immunosorbent assay to 
detect HMW adiponectin.  Diabetes 2006, 55:1954-1960.
8. Salmenniemi U, Zacharova J, Ruotsalainen E, Vauhkonen I, Pihlajamäki J, 
Kainulainen S, Punnonen K, Laakso M: Association of adiponectin level 
and variants in the adiponectin gene with glucose metabolism, energy 
expenditure, and cytokines in offspring of type 2 diabetic patients.  J 
Clin Endocrinol Metab 2006, 90:4216-4223.
9. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, 
Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, 
Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an 
insulin-sensitizing adipocyte-derived protein.  Diabetes 2002, 
51:2734-2741.
10. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, 
Saad MF, Rotter JI, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM: 
Associations of adiponectin with body fat distribution and insulin 
sensitivity in nondiabetic Hispanics and African-Americans.  J Clin 
Endocrinol Metab 2007, 92:2665-2671.
11. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, 
Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, 
Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa 
Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in 
obesity.  Biochem Biophys Res Commun 1999, 257:79-83.
12. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, 
Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, 
Matsuzawa Y: Novel modulator for endothelial adhesion molecules: 
adipocyte-derived plasma protein adiponectin.  Circulation 1999, 
100:1473-1476.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, 
Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: 
close association with insulin resistance and hiperinsulinemia.  J Clin 
Endocrinol Metab 2001, 85:1930-1935.
14. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP: 
Identification of individuals with insulin resistance using routine 
clinical measurements.  Diabetes 2005, 54:333-339.
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National 
Heart, Lung, and Blood Institute; American Heart Association: Definition 
of metabolic syndrome: report of the National Heart, Lung, and Blood 
Institute/American Heart Association conference on scientific issues 
related to definition.  Circulation 2004, 109:433-438.
16. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide 
definition. A Consensus Statement from the International Diabetes 
Federation.  Diabet Med 2006, 23:469-480.
17. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under 
two or more correlated receiver operating characteristic curves: a 
nonparametric approach.  Biometrics 1988, 44:837-845.
18. Ferrannini E, Mari A: How to measure insulin sensitivity.  J Hypertens 
1998, 16:895-906.
19. Muniyappa R, Lee S, Chen H, Quon MJ: Current approaches for assessing 
insulin sensitivity and resistance in vivo: advantages, limitations, and 
appropriate usage.  Am J Physiol Endocrinol Metab 2008, 294:E15-26.
20. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, 
Knowler WC, Krakoff J: Adiponectin and development of type 2 
diabetes in the Pima Indian population.  Lancet 2002, 360:57-8.
21. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N: 
Decreased total and high molecular weight adiponectin are 
Received: 2 April 2010 Accepted: 23 June 2010 
Published: 23 June 2010
This article is available from: http://www.cardiab.com/content/9/1/26 © 2010 Almeda-Valdes et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cardiovascular Diabetology 2010, 9:26Almeda-Valdes et al. Cardiovascular Diabetology 2010, 9:26
http://www.cardiab.com/content/9/1/26
Page 10 of 10
independent risk factors for the development of type 2 diabetes in 
Japanese-Americans.  J Clin Endocrinol Metab 2006, 91:3873-7.
22. Cruz M, García-Macedo R, García-Valerio Y, Gutiérrez M, Medina-Navarro R, 
Duran G, Wacher N, Kumate J: Low adiponectin levels predict type 2 
diabetes in Mexican children.  Diabetes Care 2004, 27:1451-3.
23. Yang WS, Chuang LM: Human genetics of adiponectin in the metabolic 
syndrome.  J Mol Med 2006, 84:112-21.
24. Basu R, Pajvani UB, Rizza RA, Scherer PE: Selective downregulation of the 
high molecular weight form of adiponectin in hiperinsulinemia and in 
type 2 diabetes: differential regulation from nondiabetic subjects.  
Diabetes 2007, 56:2174-2177.
25. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, 
Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky 
JM, Buchanan TA, Scherer PE: Complex distribution, not absolute 
amount of adiponectin, correlates with thiazolidinedione-mediated 
improvement in insulin sensitivity.  J Biol Chem 2004, 279:12152-12162.
doi: 10.1186/1475-2840-9-26
Cite this article as: Almeda-Valdes et al., Total and high molecular weight 
adiponectin have similar utility for the identification of insulin resistance Car-
diovascular Diabetology 2010, 9:26